---
title: "Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: NATiV3"
description: "Formulary evidence on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: NATiV3. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 85 evidence topics quoted from 26 sources."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence/nativ3"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: NATiV3

<a id="heading-3.1.1"></a>

## 3.1.1 NATiV3

<a id="heading-3.1.1.1"></a>

### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

#### Primary objectives of Part A and Part B in the ClinicalTrials.gov record

> “This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis stage F2 or F3 and consists of 2 sequential parts - an initial double-blind placebo-controlled (DBPC) period (Part A) followed by a double-blind active treatment extension (ATE) period (Part B), with the following primary objectives:”
> “Part A To assess the safety and efficacy of lanifibranor compared to placebo on 'NASH resolution and improvement of fibrosis' assessed by liver histology.”
> “Part B To assess the safety of lanifibranor beyond the DBPC period.”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-3.1.1.1-2"></a>

#### Key secondary and other secondary objectives in the ClinicalTrials.gov record

> “To assess the effect of lanifibranor compared to placebo on NASH resolution and no worsening of fibrosis”
> “To assess the effect of lanifibranor compared to placebo on improvement of fibrosis with no worsening of NASH”
> “To assess the effect of lanifibranor on NASH resolution and improvement of fibrosis in diabetic patients (only for DBPC period)”
> “To assess the effect of lanifibranor on liver stiffness and steatosis assessed by elastography.”
> “To assess the effect of lanifibranor on health-related quality of life”
> “To assess population PK modeling through plasma levels of lanifibranor using sparse sampling scheme (only for DBPC period)”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-3.1.1.1-3"></a>

#### Main objective in the EU Clinical Trials Information System record

> “The primary objectives of both periods in the main cohort are: • Double-blind placebo-controlled (DBPC) period (Part A) To assess the effect of lanifibranor compared to placebo on NASH resolution and improvement of fibrosis assessed by liver histology. • Double-blind active treatment extension (ATE) period (Part B) To assess the safety of lanifibranor beyond the DBPC period.”

Source: [EU Clinical Trials Information System 2023-508248-23-00](https://euclinicaltrials.eu/ctis-public/view/2023-508248-23-00)

<a id="topic-3.1.1.1-4"></a>

#### Aim of the trial stated by the company in September 2026

> “NATiV3 is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the long-term efficacy and safety of lanifibranor (800mg/daily and 1200mg/daily) in 1009 adult patients with biopsy-proven non-cirrhotic MASH and F2/F3 stage of liver fibrosis.”
> “The effect of lanifibranor will be assessed on several histological endpoints, including MASH resolution and improvement of fibrosis of at least one stage after 72 weeks of treatment.”

Source: [Inventiva NATiV3 last patient visit release (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-Inventiva-LVLP-EN-09-02-2026.pdf)

<a id="topic-3.1.1.1-5"></a>

#### Primary objectives of Part 1 and Part 2 in the original ClinicalTrials.gov record, April 2021, superseded in March 2023

> “This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis stage 2 or 3 and consists of 2 parts - Part 1 and Part 2, with the following primary objectives:”
> “Part 1 To assess the effect of lanifibranor compared to placebo on NASH resolution and improvement of fibrosis assessed by liver histology.”
> “Part 2 To assess the effect of lanifibranor compared to placebo on delaying NASH disease progression measured by a composite endpoint that includes progression to cirrhosis, liver-related clinical outcome events, or all-cause death.”
> “To assess the long-term safety (up to 7 years) of lanifibranor”

Source: [ClinicalTrials.gov NCT04849728 version 1](https://clinicaltrials.gov/study/NCT04849728?tab=history&a=1)

<a id="heading-3.1.1.2"></a>

### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

#### Study dates and status in the ClinicalTrials.gov record

> “Study Start (Actual) 2021-08-19”
> “Primary Completion (Actual) 2026-09-29”
> “Study Completion (Estimated) 2027-09-30”
> “First Posted 2021-04-19”
> “Last Update Posted 2026-11-02”
> “Active, not recruiting”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-3.1.1.2-2"></a>

#### Number of locations in the ClinicalTrials.gov record

> “This study has 459 locations”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-3.1.1.2-3"></a>

#### EU member states, trial start, and estimated end of trial in the EU Clinical Trials Information System record

> “Locations Italy, Czechia, Hungary, Bulgaria, Spain, Belgium, Poland, Germany, Portugal, France, Netherlands”
> “Start of trial 26/11/2021”
> “Estimated recruitment start date in EU/EEA: 19/01/2022”
> “Estimated end of trial date in EU/EEA: 12/12/2026”
> “Estimated global end date of the trial: 13/12/2026”

Source: [EU Clinical Trials Information System 2023-508248-23-00](https://euclinicaltrials.eu/ctis-public/view/2023-508248-23-00)

<a id="topic-3.1.1.2-4"></a>

#### Activation of the first sites in the United States, September 2021

> “The first clinical trial sites have been activated in the United States and first patients have been screened.”
> “In addition, more than 330 sites across 25 countries have already been qualified2 of which more than a third in the United States.”

Source: [Inventiva NATiV3 initiation release (2021)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Initiation-NATiV3-EN-08092021.pdf)

<a id="topic-3.1.1.2-5"></a>

#### Sites, countries, and regional distribution of randomized participants, December 2023

> “As of December 20, 2023, 468 clinical sites have been activated in 24 countries, including China, and a total of 793”
> “Approximately 70% of the patients randomized in the main and exploratory cohorts are from the United States, ~20% from Europe and ~10% from Latin America and the rest of the world.”

Source: [Inventiva NATiV3 status update release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-First-patient-randomized-in-China-and-NATiV3-status-update-EN-12-20-2023-2.pdf)

<a id="topic-3.1.1.2-6"></a>

#### Initiation, sites in Ukraine and Russia, China participation, and completion of screening and randomization stated in the Form 20-F

> “In September 2021, we initiated our NATiV3 Phase III clinical trial of lanifibranor in MASH. We completed randomization of the last patient in NATiV3 in April 2025.”
> “For example, in 2022, we put recruitment for our NATiV3 trial on hold in Ukraine and removed all of the planned sites in Russia from the NATiV3 trial due to the Russian invasion in Ukraine”
> “In December 2023, we announced that our licensee CTTQ, who joined our NATiV3 trial, randomized the first patient in China”
> “In January 2025, the Company completed screening of patients in the ongoing NATiV3 trial.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-3.1.1.2-7"></a>

#### Last patient visit of the 72-week treatment period, September 2026

> “today announced the last patient has completed their final 72-week visit in the NATiV3 Phase 3 clinical trial”
> “With the last patient having completed their final visit, all patients have completed the 72-week treatment period.”

Source: [Inventiva NATiV3 last patient visit release (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-Inventiva-LVLP-EN-09-02-2026.pdf)

<a id="topic-3.1.1.2-8"></a>

#### Estimated completion dates in the ClinicalTrials.gov record, January 2023, superseded in March 2023

> “Viewing V15 (2023-01-23)”
> “Primary Completion 2024-02 [Estimated]”
> “Study Completion 2028-09 [Estimated]”

Source: [ClinicalTrials.gov NCT04849728 version 15](https://clinicaltrials.gov/study/NCT04849728?tab=history&a=15)

<a id="heading-3.1.1.3"></a>

### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

#### Official title and design details in the ClinicalTrials.gov record

> “A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) and Fibrosis Stages F2 and F3”
> “Allocation : Randomized”
> “Interventional Model : Parallel Assignment”
> “Masking : Quadruple (ParticipantCare ProviderInvestigatorOutcomes Assessor)”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-3.1.1.3-2"></a>

#### Trial phase and transition status in the EU Clinical Trials Information System record

> “Trial Phase Therapeutic confirmatory (Phase III)”
> “Transition trial Yes”

Source: [EU Clinical Trials Information System 2023-508248-23-00](https://euclinicaltrials.eu/ctis-public/view/2023-508248-23-00)

<a id="topic-3.1.1.3-3"></a>

#### Main cohort, exploratory cohort, and active treatment extension in the company design slide

> “Noncirrhotic MASH and F2-F3 fibrosis”
> “Screen-failed patients from the main cohort”
> “noncirrhotic MASH and F1-F4 fibrosis”
> “All patients who complete the main or the exploratory cohort are eligible for the Phase 3 active treatment extension trial”
> “Stratification by fibrosis stage and diabetic status”
> “NATiV3 fully recruited: trial design mirrors the successful Phase 2b study”

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

<a id="topic-3.1.1.3-4"></a>

#### Randomization ratio, stratification factors, and amended design stated by the company

> “Patients will be randomized 1:1:1 in placebo and treatment arms (800mg/daily or 1200mg/daily of lanifibranor) and stratified based on their fibrotic stage (F2 and F3) as well as presence or absence of type 2 diabetes (T2DM).”

Source: [Inventiva NATiV3 initiation release (2021)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Initiation-NATiV3-EN-08092021.pdf)

> “The NATiV3 trial, including the amended protocol, has been designed as a double-blind, placebo-controlled global pivotal Phase 3 clinical trial to assess the potential benefit of lanifibranor treatment on liver-related clinical outcomes.”
> “After the pre-specified histological analysis, the trial will remain blinded and all patients randomized in the trial will have access to the active treatment if they decide to continue in a new active 48-week treatment extension study.”
> “A placebo-controlled exploratory cohort has been initiated in parallel to the NATiV3 trial and will include approximately 350 patients with MASH and fibrosis who are not eligible for the NATiV3 trial.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-3.1.1.3-5"></a>

#### Active treatment extension described as double-blind in the registry records

> “Part B: ATE:”
> “48 weeks after completion of DBPC period”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

> “• Double-blind active treatment extension (ATE) period (Part B) To assess the safety of lanifibranor beyond the DBPC period.”

Source: [EU Clinical Trials Information System 2023-508248-23-00](https://euclinicaltrials.eu/ctis-public/view/2023-508248-23-00)

<a id="topic-3.1.1.3-6"></a>

#### Extension described as open-label by the company in September 2026

> “Following completion of the 72-week treatment period, patients participating in NATiV3 had the option to continue into a 48-week open-label extension period, during which all patients, including those originally randomized to placebo, receive active treatment with lanifibranor.”
> “This extension will provide additional information on the longer-term safety of lanifibranor.”

Source: [Inventiva NATiV3 last patient visit release (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-Inventiva-LVLP-EN-09-02-2026.pdf)

<a id="topic-3.1.1.3-7"></a>

#### Exploratory cohort of participants histologically not eligible for the main cohort

> “An exploratory cohort has enrolled 410 patients with MASH and F1 through F4 stage of liver fibrosis.”

Source: [Inventiva NATiV3 last patient visit release (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-Inventiva-LVLP-EN-09-02-2026.pdf)

> “and in the exploratory cohort, which includes patients with MASH/NASH and fibrosis stage F1 through F4 who are histologically not eligible for the main cohort.”

Source: [Inventiva fourth NATiV3 DMC release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-4th-DMC-NATiV3-EN-05-16-2024.pdf)

<a id="topic-3.1.1.3-8"></a>

#### Central biopsy review process developed with regulatory authorities

> “We have decided to replicate several key elements of the previous Phase IIb trial, including using the same patient enrollment screening criteria, and have developed a central biopsy review process in alignment with regulatory authorities.”

Source: [Inventiva NATiV3 initiation release (2021)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Initiation-NATiV3-EN-08092021.pdf)

<a id="topic-3.1.1.3-9"></a>

#### January 2023 protocol amendments replacing Part 2 with a separate outcomes trial in compensated cirrhosis

> “Confirmatory trial of lanifibranor clinical benefits, which was initially planned to be evaluated in Part 2 of NATiV3 trial in patients with NASH and F2/F3 fibrosis, is now planned to be evaluated in a new Phase III trial in patients with NASH and compensated cirrhosis in place of the previously planned Part 2 of the NATiV3 trial”
> “1) reducing the number of biopsies a patient undergoes during the trial from three to two, 2) reducing the trial duration a patient has to consent to from 7 years to 72 weeks, 3) offering all patients in the trial access to a lanifibranor treatment for at least 48 weeks by allowing them to enter into a new active treatment extension study”

Source: [Inventiva clinical development changes release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Changes-clinical-development-of-lanifibranor-EN-01-04-2023.pdf)

> “Under the new trial design, the originally-planned Part 2 of the NATiV3 trial, a clinical outcome trial that was planned to be conducted in approximately 2,000 patients with F2 and F3 fibrosis for a maximum period of seven years, will be replaced by a placebo-controlled Phase 3 outcome trial which will be event driven and is expected to last approximately three years, depending on patient enrollment.”
> “Although the FDA’s guidance during a consultation preceding the January 2023 protocol amendments was to continue our NATiV3 trial as originally planned, the FDA did not object to the January 2023 protocol amendments”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-3.1.1.3-10"></a>

#### Amended design posted in the ClinicalTrials.gov record, March 2023

> “Viewing V16 (2023-03-30)”
> “A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )”

Source: [ClinicalTrials.gov NCT04849728 version 16](https://clinicaltrials.gov/study/NCT04849728?tab=history&a=16)

<a id="topic-3.1.1.3-11"></a>

#### Two-part design with a Part 2 clinical outcomes period in about 2,000 participants, January 2021, superseded in January 2023

> “The trial will remain blinded after the pre-specified histological analysis and continue in a total of approximately 2,000 patients until the occurrence of a pre-specified number of adverse liver-related clinical events, including progression to cirrhosis.”
> “The trial would be completed on a post-marketing basis in the event that accelerated (U.S.) / conditional (EU) approval is received.”

Source: [Inventiva NATiV3 design release (2021)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-P3-Design-EN-050121-VF.pdf)

> “Part 2 will follow the 72-week histology analysis and will assess the effect of lanifibranor (800mg/daily and 1200mg/daily) compared to placebo on delaying NASH disease progression measured by a composite endpoint that includes progression to cirrhosis, liver-related clinical outcome events, and all-cause death.”

Source: [Inventiva NATiV3 initiation release (2021)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Initiation-NATiV3-EN-08092021.pdf)

<a id="topic-3.1.1.3-12"></a>

#### Part 2 clinical outcome primary measure in the ClinicalTrials.gov record, January 2023, superseded in March 2023

> “Viewing V15 (2023-01-23)”
> “Time to first clinical outcome event”
> “Histological progression to cirrhosis (defined as histological confirmation of fibrosis score CRN F4)”
> “[Time Frame: Part 2: Date of randomisation until the End of Study (EoS) date approximately 7 years after first patient randomized]”

Source: [ClinicalTrials.gov NCT04849728 version 15](https://clinicaltrials.gov/study/NCT04849728?tab=history&a=15)

<a id="heading-3.1.1.4"></a>

### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

#### Prescreening criteria in the ClinicalTrials.gov record

> “Diagnosed with NASH on prior liver biopsy”
> “Type 2 diabetes with high waist circumference or obesity or hepatic steatosis on ultrasound”
> “At least 3 of the components of metabolic syndrome”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-3.1.1.4-2"></a>

#### Inclusion criteria in the ClinicalTrials.gov record

> “Male or female, aged ≥18 years at the time of signing informed consent”
> “Upon central biopsy reading process: diagnosis of NASH according to the Steatosis-Activity-Fibrosis (SAF):”
> “Steatosis score ≥1”
> “Activity score: A3 or A4”
> “Fibrosis score: F2 or F3”
> “Antidiabetic treatment if glucagon-like peptide-1 receptor agonists (GLP1 receptor agonists) or sodium-glucose co-transporter-2 inhibitors (SGLT2 inhibitors): for at least 3 months”
> “Vitamin E (if at a dose ≥400 IU/day): for at least 6 months”
> “Weight stable for 6 months prior to Screening and between the qualifying liver biopsy and Baseline (no more than 5% change for both periods)”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-3.1.1.4-3"></a>

#### Liver-related exclusion criteria in the ClinicalTrials.gov record

> “Documented causes of chronic liver disease other than NASH”
> “Histologically documented liver cirrhosis (fibrosis stage F4)”
> “ALT or AST >5 × ULN”
> “Haemoglobin <110 g/L (11 g/dL) for females and <120 g/L (12 g/dL) for males”
> “Patient currently receiving any approved treatment for NASH or obesity”
> “Current or recent history (<5 years) of significant alcohol consumption”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-3.1.1.4-4"></a>

#### Glycemic, obesity-related, cardiovascular, and general exclusion criteria in the ClinicalTrials.gov record

> “HbA1c >9% at Screening”
> “Diabetes mellitus other than type 2”
> “Current treatment with insulin”
> “Treatment with PPAR-gamma agonists (thiazolidinediones [TZDs]) 12 months before screening or historical biopsy.”
> “Bariatric surgery: Restrictive procedures are allowed, if performed >6 months prior to the qualifying liver biopsy; malabsorptive procedures and procedures combining both restrictive and malabsorptive methods are not allowed within 5 years of the qualifying liver biopsy.”
> “History of heart failure with reduced left ventricular ejection fraction (LVEF)”
> “Atrial fibrillation requiring anticoagulation”
> “Uncontrolled hypertension at Screening (values >160/100 mm Hg)”
> “Concomitant treatment with PPAR-alpha agonists (fibrates)”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-3.1.1.4-5"></a>

#### Concomitant GLP-1 receptor agonist allowed at a stable dose, company design slide

> “Patients under a stable dose of GLP-1-RA for at least 3 months prior to screening can be included”

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

<a id="topic-3.1.1.4-6"></a>

#### Exclusion of autoimmune liver or thyroid disease added after a suspected unexpected serious adverse reaction, February 2024

> “amendment to the protocol to exclude newly screened patients diagnosed or with a predisposition to autoimmune liver or thyroid disease.”

Source: [Inventiva preliminary full year 2023 results announcement (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Full-Year-2023-Revenue-et-Cash-EN-02-15-2024-final-1.pdf)

> “Inventiva has lifted the voluntary pause on screening and randomization in the NATiV3 clinical trial following the approval from the US central IRB of the amended protocol and ICF.”

Source: [Inventiva NATiV3 screening resumption release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-NATiV3-screening-update-EN-03-07-2024-final.pdf)

> “We decided to voluntarily pause screening and randomization to implement, including based on input from the FDA, changes to the enrollment criteria to exclude patients diagnosed or with a predisposition to autoimmune liver or thyroid disease and more frequent liver monitoring for patients enrolled in the trial as recommended by the Data Monitoring Committee.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="heading-3.1.1.5"></a>

### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

#### Treatment arms and tablets in the ClinicalTrials.gov record

> “Experimental: Lanifibranor (IVA 337) (800 mg/day)”
> “2 Lanifibranor tablets 400mg + 1 Placebo to match tablet with food --> once a day (quaque die, QD)”
> “Experimental: Lanifibranor (IVA 337) (1200 mg/day)”
> “3 Lanifibranor tablets 400mg with food --> once a day (quaque die, QD)”
> “Placebo Comparator: Matching placebo”
> “3 Placebo to match tablets with food --> once a day (quaque die, QD)”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-3.1.1.5-2"></a>

#### Randomization to two lanifibranor doses or placebo stated by the company

> “Patients will be randomized 1:1:1 to receive lanifibranor (800mg once daily or 1200mg once daily) or placebo.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-3.1.1.5-3"></a>

#### Treatment duration of the main and exploratory cohorts and the extension, company design slide

> “72 weeks of treatment”
> “lanifibranor: 1200 mg once daily”
> “lanifibranor: 800 mg once daily”
> “Placebo: once daily”
> “48 weeks”

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

<a id="topic-3.1.1.5-4"></a>

#### Active treatment with lanifibranor for all participants during the 48-week extension

> “during which all patients, including those originally randomized to placebo, receive active treatment with lanifibranor.”

Source: [Inventiva NATiV3 last patient visit release (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-Inventiva-LVLP-EN-09-02-2026.pdf)

<a id="topic-3.1.1.5-5"></a>

#### Liver monitoring every 6 weeks added for enrolled participants, March 2024

> “Inventiva chose to voluntarily pause screening and randomization of new patients in the NATiV3 trial to implement the recommendations of the independent Data Monitoring Committee”
> “which included liver monitoring every 6 weeks for each patient enrolled in the trial”

Source: [Inventiva NATiV3 screening resumption release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-NATiV3-screening-update-EN-03-07-2024-final.pdf)

<a id="heading-3.1.1.6"></a>

### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

#### 3.1.1.6.1 Rationale for Using MASH Resolution and Fibrosis Improvement of at Least One Stage as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

##### Primary outcome measure as named and defined in the ClinicalTrials.gov record

> “Resolution of NASH and improvement of fibrosis”
> “Part A: DBPC: Resolution of NASH and improvement of fibrosis at Week 72, defined by NASH CRN scores for ballooning of 0 and inflammation of 0 to 1, and fibrosis score ≥1 stage decrease compared to Baseline”
> “Part A: Date of randomisation until the date of biopsy at Week 72”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-3.1.1.6.1-2"></a>

##### Primary endpoint as a composite and the two single histologic endpoints as key secondary endpoints, company wording

> “Primary end point:”
> “Composite end point of patients having both MASH resolution and 1 stage of fibrosis improvement”
> “Key secondary end points:”
> “MASH resolution and no worsening of fibrosis, fibrosis improvement, and no worsening of MASH”

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

> “The primary composite endpoint of patients having both NASH resolution and fibrosis improvement of at least one stage will be used for the 72-week histology analysis.”
> “The endpoint is designed to predict a significant improvement of prognostic risk and, if met, may support a label for the treatment of NASH and the improvement in liver fibrosis in adult non-cirrhotic NASH patients.”
> “Endpoints of NASH resolution and no worsening of fibrosis, and improvement of fibrosis with no worsening of NASH will be included as key secondary endpoints.”

Source: [Inventiva NATiV3 design release (2021)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-P3-Design-EN-050121-VF.pdf)

<a id="topic-3.1.1.6.1-3"></a>

##### Single histologic endpoints named key primary or key secondary endpoints in the company's financing terms

> “The exercise of the T3 BSAs is subject to the T3 Triggering Event, i.e., release by the Company of topline data announcing that any key primary endpoint or key secondary endpoint of NATiV3 (resolution of NASH without worsening fibrosis and improvement of liver fibrosis without worsening NASH), with any dosage regimen tested in the trial, have been met no later than June 15, 2027.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-3.1.1.6.1-4"></a>

##### Primary outcome measure titled resolution of NASH in the original ClinicalTrials.gov record, April 2021, superseded in October 2021

> “Viewing V1 (2021-04-16)”
> “Resolution of NASH”
> “Resolution of NASH and improvement of fibrosis at Week 72, defined by NASH CRN scores for ballooning of 0 and inflammation of 0 to 1, and fibrosis score ≥1 stage decrease compared to Baseline”
> “[Time Frame: Date of randomisation until the date of biopsy at Week 72]”

Source: [ClinicalTrials.gov NCT04849728 version 1](https://clinicaltrials.gov/study/NCT04849728?tab=history&a=1)

<a id="topic-3.1.1.6.1-5"></a>

##### Composite endpoint carried over from the phase 2b NATIVE trial

> “The primary composite endpoint of part 1 of the NATiV3 Phase III clinical trial is identical to the composite efficacy endpoint used in Inventiva’s NATIVE Phase IIb clinical trial which was met by both lanifibranor doses with statistical significance, including in NASH patients with F2/F3 fibrosis and NASH patients with type 2 diabetes (T2DM).”
> “During the NATIVE Phase IIb trial, 21% and 31% of patients in the lanifibranor 800mg/day and 1200mg/day dose groups respectively achieved the Phase III primary composite endpoint after only 24 weeks of treatment compared to 7% in the placebo arm.”

Source: [Inventiva NATiV3 initiation release (2021)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Initiation-NATiV3-EN-08092021.pdf)

<a id="topic-3.1.1.6.1-6"></a>

##### Phase 2b effect on the composite endpoint by type 2 diabetes status cited for NATiV3

> “The effect size of lanifibranor therapy over placebo in the Phase IIb clinical trial on the composite endpoint”
> “(which corresponds to the primary efficacy endpoint in the NATiV3 Phase III clinical trial), was”
> “higher in patients with T2D than in patients without diabetes: 21% and 26% for lanifibranor 800 and 1200 mg/day, respectively, in patients with T2D compared to 7% and 22%, respectively, in patients without T2D.”

Source: [Inventiva NATiV3 status update release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-First-patient-randomized-in-China-and-NATiV3-status-update-EN-12-20-2023-2.pdf)

<a id="topic-3.1.1.6.1-7"></a>

##### FDA draft guidance: histologic endpoints reasonably likely to predict clinical benefit for accelerated approval

> “Because of the slow progression of NASH and the time required to conduct a trial that”
> “recommends sponsors consider the following liver histological improvements as”
> “endpoints reasonably likely to predict clinical benefit to support accelerated approval”
> “Resolution of steatohepatitis on overall histopathological reading and no worsening”
> “Improvement in liver fibrosis greater than or equal to one stage (NASH CRN fibrosis”
> “Both resolution of steatohepatitis and improvement in fibrosis (as defined above).”

Source: [FDA (2018)](https://www.fda.gov/media/119044/download)

<a id="topic-3.1.1.6.1-8"></a>

##### FDA draft guidance: confirmatory outcome trials underway at submission and the composite clinical endpoint

> “For NASH drugs approved on the basis of liver histology under the accelerated approval”
> “pathway, randomized, double-blind, placebo-controlled clinical trials designed to”
> “describe and verify the drug’s clinical benefit should be underway at the time of”
> “submission of the marketing application.  Clinical benefit can be verified by”
> “demonstrating superiority to placebo in delaying disease progression measured by a”

Source: [FDA (2018)](https://www.fda.gov/media/119044/download)

<a id="topic-3.1.1.6.1-9"></a>

##### EMA reflection paper: two composite histologic endpoints required as co-primary endpoints for conditional approval

> “Acceptable intermediate endpoints would consist of two composite endpoints to be evaluated at the”
> “The resolution of NASH – with the presence of any grade of steatosis, and all of the following: No”
> “ballooning, only minimal (grade 1) lobular inflammation and – no worsening of the stage of fibrosis.”
> “The improvement of fibrosis by at least 1 stage without any worsening of NASH (no worsening of”
> “Efficacy for both endpoints should be demonstrated in co-primary fashion, meaning that both will have”
> “to independently demonstrate a statistically significant and clinically relevant difference to placebo.”

Source: [European Medicines Agency NASH reflection paper (2024)](https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-regulatory-requirements-development-medicinal-products-non-alcoholic-steatohepatitis-nash_en.pdf)

<a id="topic-3.1.1.6.1-10"></a>

##### Regulatory consultation before the trial: accelerated and conditional approval on the 72-week histology analysis

> “today announced the details of the Phase III clinical trial with its lead drug candidate lanifibranor in NASH following the end-of-phase II meeting with the U.S. Food and Drug Administration (FDA) and the receipt of the Scientific Advice letter from the European Medicines Agency (EMA).”
> “Inventiva will seek to obtain accelerated approval in the U.S. and conditional approval in the EU for lanifibranor based on a pre-specified histology analysis in approximately 900 patients after 72 weeks establishing a positive benefit-risk ratio.”
> “The duration of 72 weeks was considered adequate by both the FDA and EMA to establish long-term use as well as dose and cumulative drug exposure.”

Source: [Inventiva NATiV3 design release (2021)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-P3-Design-EN-050121-VF.pdf)

<a id="topic-3.1.1.6.1-11"></a>

##### Accelerated approval on histologic endpoints and confirmation in a separate outcomes trial after the January 2023 amendments

> “The protocol amendments, submitted to the FDA in January 2023, were designed to align with an FDA public communication suggesting that an alternative approach to seek full approval in patients with MASH could be considered upon submission of positive results of a Phase 3 trial using a histology surrogate endpoint in patients with MASH and a Phase 3 clinical outcome trial in patients with MASH and compensated cirrhosis.”
> “We anticipate submission of an NDA to the FDA for accelerated approval based on liver histological endpoints of approximately 950 patients treated over a 72-week period for our Phase 3 trial, if the data is positive.”
> “We may seek accelerated approval from the FDA and conditional authorization from the European Commission if our NATiV3 Phase 3 clinical trial of lanifibranor in MASH is successful at the 72-week endpoint but, even if granted, accelerated approval and conditional authorization require completion of the trial to obtain full approval.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-3.1.1.6.1-12"></a>

##### Precedent: accelerated approval of resmetirom based on the two single histologic endpoints

> “This indication is approved under accelerated approval based on improvement of MASH and fibrosis [see Clinical Studies (14)].”
> “Efficacy determination was based on the effect of REZDIFFRA on resolution of steatohepatitis without worsening of fibrosis and one stage improvement in fibrosis without worsening of steatohepatitis, on post-baseline liver biopsies collected at 12 months.”
> “Two pathologists, Pathologist A and Pathologist B, independently read the liver biopsies for each patient.”

Source: [Madrigal Pharmaceuticals REZDIFFRA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217785s006lbl.pdf)

<a id="topic-3.1.1.6.1-13"></a>

##### Reliability of NASH CRN histologic scoring between readers in a phase 2 trial

> “Inter-reader linearly weighted kappas were 0.609, 0.484, 0.328, and 0.517 for steatosis, fibrosis, lobular inflammation, and ballooning, respectively.”
> “Inter-reader unweighted kappas were 0.400 for the diagnosis of NASH, 0.396 for NASH resolution without worsening fibrosis, and 0.366 for fibrosis improvement without worsening NASH.”
> “Simulations show that the lack of reliability of endpoints and inclusion criteria can drastically reduce study power - from >90% in a well-powered study to as low as 40%.”

Source: [Davison et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32610115/)

<a id="topic-3.1.1.6.1-14"></a>

##### EMA reflection paper: observer variability of the NASH CRN system and centralized reading by at least two histopathologists

> “The inter- and intra-observer variability for some of the features of the CRN-system has been revealed”
> “order to limit variability of the methods, use of centralised evaluation by at least two experienced”
> “histopathologists, including algorithms for arbitration is recommended.”

Source: [European Medicines Agency NASH reflection paper (2024)](https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-regulatory-requirements-development-medicinal-products-non-alcoholic-steatohepatitis-nash_en.pdf)

<a id="topic-3.1.1.6.1-15"></a>

##### Digital versus glass slide reading of NATiV3 screening biopsies, AASLD 2025 poster

> “Presentation of a comparison between digital and glass slide histology from screening biopsies in the Phase 3 NATiV3 study”
> “Comparison of digital images versus glass slides for the histopathological evaluation of liver biopsy samples according to the NASH-CRN scoring system for MASH: A validation performed as part of the NATiV3 study”
> “C. Lackner, Z. Goodman, D. Tiniakos, P. Hytiroglou, A. Sanyal, S. Francque, P. Huot-”

Source: [Inventiva AASLD 2025 abstracts release (2025)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-AASLD-Abstracts-2025-EN-10-07-2025-1.pdf)

<a id="topic-3.1.1.6.1-16"></a>

##### Validation of whole slide images against glass slides for steatohepatitis scoring in clinical trials

> “The results from this validation study support the conclusion that the WSI IMS platform is equivalent to the glass read in reference to a robust glass GT when used by pathologists to evaluate steatohepatitis trial populations for diagnosis and trial‐based scoring criteria and histologic feature scoring during enrollment and for follow‐up timepoints.”

Source: [Pulaski et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11410674/)

<a id="topic-3.1.1.6.1-17"></a>

##### FDA statements on noninvasive biomarkers as replacements for liver biopsy

> “FDA encourages sponsors to identify biochemical or noninvasive imaging biomarkers”
> “that could eventually replace liver biopsies.  Sponsors could use such biomarkers, once”
> “characterized and agreed upon by the FDA, either for patient selection or for assessing”

Source: [FDA (2018)](https://www.fda.gov/media/119044/download)

> “[8/27/2025] FDA's Center for Drug Evaluation and Research, Office of New Drugs has accepted a Letter of Intent for the qualification of Liver Stiffness Measurement by Vibration-Controlled Transient Elastography as a reasonably likely surrogate endpoint for clinical trials in adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver fibrosis (scarring).”
> “This acceptance represents the first step in the Drug Development Tool qualification process, where the company will work with FDA to develop a comprehensive qualification plan for data and validation requirements to support the specific context of use.”

Source: [FDA (2025)](https://www.fda.gov/drugs/drug-alerts-and-statements/fda-accepts-proposal-reasonably-likely-surrogate-endpoint-mash-all-cause-mortality-or-liver-related)

<a id="topic-3.1.1.6.1-18"></a>

##### Noninvasive tests in the exploratory cohort

> “Approximately 200 screen-failed patients from Part 1 of the NATiV3 trial are expected to be included in a new 72-week exploratory cohort aimed at generating results based on non-invasive tests and contributing to the regulatory safety database”

Source: [Inventiva clinical development changes release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Changes-clinical-development-of-lanifibranor-EN-01-04-2023.pdf)

<a id="heading-3.1.1.7"></a>

### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

#### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

##### Estimated enrollment in the ClinicalTrials.gov record

> “Enrollment (Estimated) 1000”
> “A total of 1000 patients will be randomised to receive lanifibranor (800 mg/day) or lanifibranor (1200 mg/day), or matching placebo, employing a 1:1:1 randomisation scheme, respectively, without interruption between Part A and Part B.”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-3.1.1.7.1-2"></a>

##### Enrollment targets and participants randomized in the main and exploratory cohorts, April 2025

> “Inventiva has enrolled 1009 patients in the main cohort and 410 patients in the exploratory cohort exceeding the original target of 969 and 350, respectively.”

Source: [Inventiva NATiV3 enrollment completion release (2025)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-End-of-Patient-Randomization-EN-04-01-2025.pdf)

<a id="topic-3.1.1.7.1-3"></a>

##### Statistical power for the sample size calculation and enrollment, company design slide

> “90% considered for sample size calculations”
> “NATiV3 fully recruited with 1009 patients in the main cohort and 410 in the exploratory cohort”

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

<a id="topic-3.1.1.7.1-4"></a>

##### Participants planned for the histologic analysis supporting the NDA, Form 20-F

> “We anticipate submission of an NDA to the FDA for accelerated approval based on liver histological endpoints of approximately 950 patients treated over a 72-week period for our Phase 3 trial, if the data is positive.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-3.1.1.7.1-5"></a>

##### Enrolled main cohort stated in September 2026

> “NATiV3 enrolled 1,009 adults with biopsy-proven non-cirrhotic MASH and F2/F3 fibrosis, with an additional 410 patients enrolled in an exploratory cohort.”

Source: [Inventiva NATiV3 last patient visit release (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-Inventiva-LVLP-EN-09-02-2026.pdf)

<a id="topic-3.1.1.7.1-6"></a>

##### Estimated enrollment of 2000 in the ClinicalTrials.gov record, April 2021, superseded in March 2023

> “Viewing V1 (2021-04-16)”
> “Enrollment 2000 [Estimated]”
> “A total of 2000 patients will be randomised to receive lanifibranor (800 mg/day) or lanifibranor (1200 mg/day), or matching placebo, employing a 1:1:1 randomisation scheme, respectively, without interruption between Part 1 and Part 2.”

Source: [ClinicalTrials.gov NCT04849728 version 1](https://clinicaltrials.gov/study/NCT04849728?tab=history&a=1)

<a id="topic-3.1.1.7.1-7"></a>

##### Planned histology analysis in about 900 participants, January 2021, superseded in April 2025

> “Seeking of U.S. accelerated approval and EU conditional approval for lanifibranor to be based on 72-week histology analysis in approximately 900 patients”
> “Statistical powering of 90% was considered for the sample size calculations of the Phase III clinical trial.”

Source: [Inventiva NATiV3 design release (2021)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-P3-Design-EN-050121-VF.pdf)

<a id="topic-3.1.1.7.1-8"></a>

##### Planned exploratory cohort of about 200 participants, December 2023, superseded in April 2025

> “The trial takes place in 24 countries and in more than 400 clinical sites and to recruit approximately 900 patients to be treated over a 72-week period.”
> “An exploratory cohort is anticipated to enrol approximately 200 patients with NASH and fibrosis screen-failed on histology for the main NATiV3 clinical trial.”

Source: [Inventiva NATiV3 status update release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-First-patient-randomized-in-China-and-NATiV3-status-update-EN-12-20-2023-2.pdf)

<a id="heading-3.1.1.7.2"></a>

#### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

##### Analysis periods for the Part B safety analyses in the ClinicalTrials.gov record

> “Using the DBPC on-treatment period, comparing the 2 active arms versus placebo”
> “Using the DBPC +ATE on treatment periods, assessing the 2 active arms. For adverse events, adjudicated liver events, and DILI and MACE events, in addition to the raw cumulative incidence proportions, the exposure-adjusted incidence rates will be provided based on the time patients are at risk.”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-3.1.1.7.2-2"></a>

##### Histologic analysis population and exploratory cohort contribution to the safety database, Form 20-F

> “We anticipate submission of an NDA to the FDA for accelerated approval based on liver histological endpoints of approximately 950 patients treated over a 72-week period for our Phase 3 trial, if the data is positive.”
> “We anticipate that this exploratory cohort may generate additional results using non-invasive tests and contribute to the safety database requirement to support the planned submission for potential accelerated approval.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="heading-3.1.1.8"></a>

### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

#### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

##### Completion of randomization in the main and exploratory cohorts and the drop-out condition, April 2025

> “today announced the completion of patient enrollment in its NATiV3 Phase 3 clinical trial with the randomization of the last patient in the main cohort.”
> “(ii) at the time of completion of enrollment in NATiV3, a drop-out rate of less than 30% before week 72.”

Source: [Inventiva NATiV3 enrollment completion release (2025)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-End-of-Patient-Randomization-EN-04-01-2025.pdf)

<a id="topic-3.1.1.8.1-2"></a>

##### Completion of the 72-week treatment period by all participants, September 2026

> “Last patient completed final 72-week visit in NATiV3, with 1,009 patients enrolled in the main cohort and 410 patients in the exploratory cohort”
> “With the last patient having completed their final visit, all patients have completed the 72-week treatment period.”

Source: [Inventiva NATiV3 last patient visit release (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-Inventiva-LVLP-EN-09-02-2026.pdf)

<a id="topic-3.1.1.8.1-3"></a>

##### Participants remaining to complete the 72-week biopsy, October 2025

> “Only a few hundred patients remaining to complete their 72-week biopsy”

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

<a id="topic-3.1.1.8.1-4"></a>

##### Randomized participants, screening, and screen failure rate, December 2023

> “As of December 20, 2023, a total of 793 patients have been randomized in NATiV3 of which 657 in the main cohort and 136 in the exploratory cohort.”
> “are in the screening process and, based on the recent screen failure rate of approximately 80%, Inventiva expects”
> “As of December 20, 2023, 136 patients are randomised in the exploratory cohort including approximately 30% of patients with fibrosis stage F4.”

Source: [Inventiva NATiV3 status update release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-First-patient-randomized-in-China-and-NATiV3-status-update-EN-12-20-2023-2.pdf)

<a id="topic-3.1.1.8.1-5"></a>

##### Participants randomized before the voluntary screening pause, February 2024

> “Prior to the voluntary pause, 913 patients were already randomized in the NATiV3 clinical trial including 731 in the main cohort and over 550 patients were in screening.”
> “This is an important milestone as 152 sites of the NATiV3 clinical trial sites are operating under central IRB and have so far randomized over 60% of the patients in the main cohort.”

Source: [Inventiva NATiV3 screening resumption release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-NATiV3-screening-update-EN-03-07-2024-final.pdf)

<a id="topic-3.1.1.8.1-6"></a>

##### Treatment duration of participants at the fifth Data Monitoring Committee review, October 2024

> “Among the more than 1000 patients whose data was reviewed, over 800 patients have been treated for more than 24 weeks, the treatment duration evaluated in the Phase 2b, NATIVE, study, and 177 patients have been treated for more than 72 weeks.”

Source: [Inventiva fifth NATiV3 DMC release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-5th-DMC-NATiV3-EN-10-30-2024-1.pdf)

<a id="topic-3.1.1.8.1-7"></a>

##### Screen failure rate and enrollment delays stated in the Form 20-F

> “which, together with higher than originally projected screen failure rate resulting in a slower than anticipated enrollment rate, contributed to a delay in patient enrollment.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="heading-3.1.1.8.2"></a>

#### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

##### Demographic and metabolic characteristics of the NATiV3 main cohort compared with NATIVE, company slides

| Characteristic | NATiV3 (main cohort) | NATIVE |
| --- | --- | --- |
| Participants | “NATiV3 N=1009” | “NATIVE N=247” |
| Female | “59%” | “58%” |
| Male | “41%” | “42%” |
| Weight (kg), mean (SD) | “97.10”; “(± 23.6)” | “93.30”; “(± 18.8)” |
| BMI class obese (30 or more) | “75%” | “65%” |
| Type 2 diabetes | “55%” | “42%” |
| HOMA-IR, mean (SD) | “9.8”; “(± 10.2)” | “10.1”; “(± 12.7)” |
| HbA1c, mean (SD) | “6.5%”; “(± 1.0)” | “6.0%”; “(± 0.7)” |
| Adiponectin (µg/mL), mean (SD) | “4.6”; “(± 2.7)” | “5.1”; “(± 2.7)” |

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

> “Baseline characteristics of NATiV3 are aligned with those of Phase 2b NATIVE”
> “median: NATiV3 = 95kg | NATIVE = 92kg”
> “median: NATiV3 = 7.3 | NATIVE = 6.7”
> “median: NATiV3 = 6.2% | NATIVE = 5.9%”
> “median: NATiV3 = 4.0 | NATIVE = 4.5”

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

<a id="topic-3.1.1.8.2-2"></a>

##### Liver disease characteristics of the NATiV3 main cohort compared with NATIVE, company slides

| Characteristic | NATiV3 (main cohort) | NATIVE |
| --- | --- | --- |
| Fibrosis stage F2 | “33.0%” | “41.3%” |
| Fibrosis stage F3 | “67.0%” | “34.8%” |
| Liver stiffness measurement (kPa), median | “10.1” | “8.9” |
| Controlled attenuation parameter (dB/m), median | “329” | “327” |
| ALT (U/L), median | “50” | “51” |
| AST (U/L), median | “40” | “37” |
| FIB-4 score, median | “1.35” | “1.19” |
| ELF score, median | “9.6” | “9.7” |

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

> “mean ±SD: NATiV3 = 11.1 ± 4.9 | NATIVE = 10.09 ± 5.02”
> “mean ±SD: NATiV3 = 324 ± 48 | NATIVE = 327.7 ± 43.2”
> “mean ±SD: NATiV3 = 59 ± 36 | NATIVE = 62 ± 39”
> “mean ±SD: NATiV3 = 47 ± 26 | NATIVE = 47 ± 32”
> “mean ±SD: NATiV3 = 1.49 ± 0.75 | NATIVE = 1.41 ± 0.87”
> “mean ±SD: NATiV3 = 9.7 ± 0.9 | NATIVE = 9.7 ± 1.0”

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

<a id="topic-3.1.1.8.2-3"></a>

##### Concomitant SGLT2 inhibitor and GLP-1 receptor agonist use at baseline in the NATiV3 main cohort compared with NATIVE, company slides

| Co-medication at baseline | NATiV3 (main cohort) | NATIVE |
| --- | --- | --- |
| SGLT2 inhibitor, yes | “10.0%” | “2.8%” |
| SGLT2 inhibitor, no | “90.0%” | “97.2%” |
| GLP-1 receptor agonist, yes | “14.0%” | “0.0%” |
| GLP-1 receptor agonist, no | “86.0%” | “0.0%” |

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

<a id="topic-3.1.1.8.2-4"></a>

##### Interim baseline characteristics of participants randomized in the main cohort, December 2023

> “At baseline, 13% of patients randomized in the main cohort are receiving a stable dose GLP1 receptor agonists and 8% are receiving stable SGLT2 inhibitors.”
> “The main difference in patient characteristics observed thus far is that there is a higher percentage of patients with type 2 diabetes (T2D) in the main cohort of the NATiV3 Phase III trial compared to the NATIVE Phase IIb trial (55% vs 42%, respectively).”

Source: [Inventiva NATiV3 status update release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-First-patient-randomized-in-China-and-NATiV3-status-update-EN-12-20-2023-2.pdf)

<a id="heading-3.1.1.8.3"></a>

#### 3.1.1.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.1.8.4"></a>

#### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

#### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

##### Treatment-related suspected unexpected serious adverse reaction of elevated aminotransferases, February 2024

> “This event has been assessed as a treatment-related Suspected Unexpected Serious”
> “The study drug was discontinued for that patient and liver tests which are being closely followed at the clinical site are improving and the patient has been without clinical symptoms throughout the period of observation.”
> “Additional lab tests and a liver biopsy performed after study drug discontinuation provided results compatible with autoimmune hepatitis.”
> “This patient presented at baseline in September 2022 with a histological diagnosis of NASH with stage 2 fibrosis. An earlier diagnostic analysis had raised a suspicion of autoimmune hepatitis dating back to June 2022.”
> “This SUSAR is the first reported in all clinical trials with lanifibranor.”

Source: [Inventiva preliminary full year 2023 results announcement (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Full-Year-2023-Revenue-et-Cash-EN-02-15-2024-final-1.pdf)

<a id="topic-3.1.1.8.5-2"></a>

##### Other milder aminotransferase elevations among trial participants, Form 20-F

> “Other milder cases of elevation of aminotransferases among trial participants have also been reported.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-3.1.1.8.5-3"></a>

##### Recovery of the participant with the suspected unexpected serious adverse reaction, May 2024

> “The patient who experienced the adverse event of increased liver test results, which was reported as a SUSAR, has been without clinical symptoms throughout the period of observation and has fully recovered.”

Source: [Inventiva fourth NATiV3 DMC release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-4th-DMC-NATiV3-EN-05-16-2024.pdf)

<a id="topic-3.1.1.8.5-4"></a>

##### Third Data Monitoring Committee review of blinded safety data, December 2023

> “The DMC review supports the continuation of the NATiV3 clinical trial, in the absence of a  safety signal that would require any modification to the trial protocol.”
> “This safety assessment was based on the review of safety data from more than 500 patients, including patients that have been treated with lanifibranor for more than 72 weeks.”

Source: [Inventiva third NATiV3 DMC release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-3rd-DMC-NATiV3-EN-12-04-2023.pdf)

<a id="topic-3.1.1.8.5-5"></a>

##### Fourth Data Monitoring Committee review of unblinded safety data, May 2024

> “The recommendation was based on the unblinded review by the DMC of safety data from more than 900 patients randomized in the main and exploratory cohorts, including more than 360 and 80 patients that have been treated for more than 48 and 72 weeks, respectively.”

Source: [Inventiva fourth NATiV3 DMC release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-4th-DMC-NATiV3-EN-05-16-2024.pdf)

<a id="topic-3.1.1.8.5-6"></a>

##### Fifth Data Monitoring Committee review of unblinded safety data, October 2024

> “The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data.”
> “The safety data was unblinded to the DMC but remains blinded with respect to the Company.”

Source: [Inventiva fifth NATiV3 DMC release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-5th-DMC-NATiV3-EN-10-30-2024-1.pdf)

<a id="heading-3.1.1.9"></a>

### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

#### Summary: results not yet reported and blinded safety information

The ClinicalTrials.gov record gives an actual primary completion date of 2026-09-29 and an estimated study completion date of 2027-09-30. All participants had completed the 72-week treatment period, and Inventiva expected to report topline results in the fourth quarter of 2026. The safety information available comes from company statements on Data Monitoring Committee reviews: one review used safety data from more than 500 participants, including participants treated with lanifibranor for more than 72 weeks; another used unblinded data from more than 900 participants randomized in the main and exploratory cohorts; and at another the data were unblinded to the committee and remained blinded with respect to the company.

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728); [Inventiva NATiV3 last patient visit release (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-Inventiva-LVLP-EN-09-02-2026.pdf); [Inventiva first half 2026 results announcement (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-H1-2026-Financial-Results-EN-09-28-2026.pdf); [Inventiva third NATiV3 DMC release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-3rd-DMC-NATiV3-EN-12-04-2023.pdf); [Inventiva fourth NATiV3 DMC release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-4th-DMC-NATiV3-EN-05-16-2024.pdf); [Inventiva fifth NATiV3 DMC release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-5th-DMC-NATiV3-EN-10-30-2024-1.pdf)

<a id="topic-3.1.1.9-2"></a>

#### Summary: histologic surrogate endpoint, endpoint naming, and reader variability

- The primary outcome is histologic: resolution of NASH and improvement of fibrosis at week 72, defined by NASH CRN scores for ballooning of 0, inflammation of 0 to 1, and a fibrosis decrease of at least 1 stage. Inventiva states that accelerated approval and conditional authorization, even if granted, require completion of the trial to obtain full approval.
- The January 2023 protocol amendments replaced the planned Part 2 of NATiV3, a clinical outcome trial in approximately 2,000 participants with F2 and F3 fibrosis for a maximum of seven years, with a separate event-driven phase 3 outcome trial in participants with compensated cirrhosis. The Form 20-F states that the FDA's guidance during a consultation preceding the amendments was to continue NATiV3 as originally planned, and that the FDA did not object to the amendments.
- Sources name the endpoints differently. The ClinicalTrials.gov record names the composite of NASH resolution and fibrosis improvement as the primary outcome, and the investor and analyst day presentation names the composite as the primary endpoint and the two single histologic endpoints as key secondary endpoints. The financing terms in the Form 20-F describe the two single endpoints as “key primary endpoint or key secondary endpoint”. The original registry version (April 2021) titled the primary measure "Resolution of NASH" while defining it as the composite. Efficacy for the accelerated approval of resmetirom was determined on the two single endpoints, and the EMA reflection paper states that efficacy for both endpoints (resolution of NASH and improvement of fibrosis by at least 1 stage) should be demonstrated in co-primary fashion.
- Davison et al. reported inter-reader unweighted kappas of 0.396 for NASH resolution without worsening fibrosis and 0.366 for fibrosis improvement without worsening NASH, and simulations in which unreliable endpoints and inclusion criteria reduced study power from >90% to as low as 40%.

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728); [ClinicalTrials.gov NCT04849728 version 1](https://clinicaltrials.gov/study/NCT04849728?tab=history&a=1); [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf); [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm); [Madrigal Pharmaceuticals REZDIFFRA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217785s006lbl.pdf); [European Medicines Agency NASH reflection paper (2024)](https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-regulatory-requirements-development-medicinal-products-non-alcoholic-steatohepatitis-nash_en.pdf); [Davison et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32610115/)

<a id="topic-3.1.1.9-3"></a>

#### Summary: enrollment figures, protocol amendments, and the extension period

- Enrollment figures differ by source and date. The ClinicalTrials.gov record gives an estimated enrollment of 1000 (2000 in the April 2021 version). Inventiva reports 1,009 participants in the main cohort and 410 in the exploratory cohort, exceeding the original targets of 969 and 350. The Form 20-F anticipates an NDA based on histologic endpoints in approximately 950 patients, and the NATiV3 design release planned the histology analysis in approximately 900 patients.
- The January 2023 amendments reduced the number of biopsies per participant from three to two and the trial duration a participant consents to from 7 years to 72 weeks. In 2022, recruitment was put on hold in Ukraine and all planned sites in Russia were removed.
- A treatment-related suspected unexpected serious adverse reaction of elevated aminotransferases, with biopsy results compatible with autoimmune hepatitis, led to a voluntary pause in screening and randomization, an amendment excluding newly screened patients diagnosed with or predisposed to autoimmune liver or thyroid disease, and liver monitoring every 6 weeks. Before the pause, 913 participants had been randomized, including 731 in the main cohort.
- The ClinicalTrials.gov and EU Clinical Trials Information System records describe the 48-week Part B extension as double-blind; the company's last patient visit release describes it as open-label, with all participants, including those originally randomized to placebo, receiving lanifibranor.

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728); [ClinicalTrials.gov NCT04849728 version 1](https://clinicaltrials.gov/study/NCT04849728?tab=history&a=1); [Inventiva NATiV3 enrollment completion release (2025)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-End-of-Patient-Randomization-EN-04-01-2025.pdf); [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm); [Inventiva NATiV3 design release (2021)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-P3-Design-EN-050121-VF.pdf); [Inventiva clinical development changes release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Changes-clinical-development-of-lanifibranor-EN-01-04-2023.pdf); [Inventiva preliminary full year 2023 results announcement (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Full-Year-2023-Revenue-et-Cash-EN-02-15-2024-final-1.pdf); [Inventiva NATiV3 screening resumption release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-NATiV3-screening-update-EN-03-07-2024-final.pdf); [EU Clinical Trials Information System 2023-508248-23-00](https://euclinicaltrials.eu/ctis-public/view/2023-508248-23-00); [Inventiva NATiV3 last patient visit release (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-Inventiva-LVLP-EN-09-02-2026.pdf)

<a id="topic-3.1.1.9-4"></a>

#### Summary: enrolled population and generalizability

- Inventiva reported a recent screen failure rate of approximately 80% in December 2023, and the Form 20-F states that a higher than originally projected screen failure rate slowed enrollment.
- The main cohort differs from the NATIVE population in company slides: type 2 diabetes 55% versus 42%, fibrosis stage F3 67.0% versus 34.8%, obesity 75% versus 65%, GLP-1 receptor agonist use at baseline 14.0% versus 0.0%, and SGLT2 inhibitor use 10.0% versus 2.8%.
- As of December 2023, approximately 70% of participants randomized in the main and exploratory cohorts were from the United States, approximately 20% from Europe, and approximately 10% from Latin America and the rest of the world.
- Exclusion criteria include HbA1c >9% at screening, current insulin treatment, history of heart failure with reduced left ventricular ejection fraction, atrial fibrillation requiring anticoagulation, current approved treatment for NASH or obesity, thiazolidinedione treatment in the prior 12 months, and hemoglobin <11 g/dL in females or <12 g/dL in males.

Source: [Inventiva NATiV3 status update release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-First-patient-randomized-in-China-and-NATiV3-status-update-EN-12-20-2023-2.pdf); [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm); [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf); [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations.md)
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references.md)
